Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXTENZA for Post-Vitrectomy Pain, Inflammation, and CME
NCT04501367Phase 4Unknown
- Sponsor
- Kovach Eye Institute
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozurdex in postoperative pain, post-operative inflammation, cystoid macular edema (CME), sponsored by Kovach Eye Institute. Status: unknown.
02
Drugs
ozurdex
03
Conditions
postoperative painpost-operative inflammationcystoid macular edema (CME)
Beyond the preview
Go deeper on NCT04501367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501367.